This patented technology introduces a fundamentally new approach to manufacturing therapeutic biomolecules. Traditional peptide synthesis relies on hazardous chemical reagents, generates substantial organic waste, and consumes significant energy — limiting scalability and sustainability. Our invention solves these challenges through a novel electrochemical method. By applying controlled anodic oxidation in alkaline media, we enable direct peptide bond formation using electrons as the cleanest possible reagent. No stoichiometric coupling agents. No toxic byproducts. No extensive solvent waste. Key technical advantages: • Coupling yields exceeding 95% with product purity above 97% • Energy consumption reduced by 65% compared to traditional solid-phase synthesis • Synthesis time reduced from 18 hours to 5 hours for a 10-mer antimicrobial peptide • Scalable continuous-flow reactor design compatible with GMP manufacturing • Compatible with therapeutic peptides, modified oligonucleotides, and glycoconjugates The core innovation leverages electrode architectures originally developed for industrial electrochemical processes, adapted for biocompatibility and precise biomolecule assembly. This technology transfer from materials science to biomanufacturing opens new pathways for sustainable pharmaceutical production. Intellectual property status: • International Patent Application (PCT) pending • 7 claims covering method, reactor system, and product-by-process • IPC Classification: C07K 1/02; C07K 1/04; C07H 21/00; C25B 3/00; C25B 9/00 • Inventor: Artem G. Teplov | ORCID: 0009-0000-0049-5232 Commercial opportunity: The global therapeutic peptide market exceeds $50 billion and is growing rapidly, driven by demand for GLP-1 analogs, antimicrobial peptides, and personalized medicines. Our platform addresses critical pain points for CDMOs and biopharma companies: cost reduction, waste minimization, and scalable green chemistry. Licensing framework: • Non-exclusive evaluation license available for full technical documentation and reactor specifications • Commercial licensing negotiable based on molecule class, territory, and production volume • Open to joint R&D partnerships, pilot deployment collaborations, and equity investment in scale-up ventures Impact alignment: This technology directly supports UN Sustainable Development Goals 3 (Good Health), 9 (Industry & Innovation), and 12 (Responsible Consumption) by enabling cleaner, more efficient production of life-saving therapeutics. For licensing inquiries, technical collaboration, or investment discussions: Email: Teplov.a.g@gmail.com